User profiles for M Azim Ansari
 | M. Azim AnsariOxford University Verified email at ndm.ox.ac.uk Cited by 5222 |
[HTML][HTML] Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
and therapeutics will depend on understanding viral immunity. We studied T cell memory …
[PDF][PDF] Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …
SARS-CoV-2 within-host diversity and transmission
…, G Vernet, A Justice, A Green, SM Nicholls, MA Ansari… - Science, 2021 - science.org
INTRODUCTION Genome sequencing at an unprecedented scale during the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is helping to track spread of the …
respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is helping to track spread of the …
[HTML][HTML] T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre …
Background Previous infection with SARS-CoV-2 affects the immune response to the first
dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and …
dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and …
[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical …
Background Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40
million people globally living with HIV who might have less functional immunity and more …
million people globally living with HIV who might have less functional immunity and more …
[PDF][PDF] A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete
description of specific immune biomarkers. We present here a comprehensive multi-omic …
description of specific immune biomarkers. We present here a comprehensive multi-omic …
[HTML][HTML] Microevolutionary analysis of Clostridium difficile genomes to investigate transmission
Background The control of Clostridium difficile infection is a major international healthcare
priority, hindered by a limited understanding of transmission epidemiology for these bacteria. …
priority, hindered by a limited understanding of transmission epidemiology for these bacteria. …
[HTML][HTML] T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
Identification of protective T cell responses against SARS-CoV-2 requires distinguishing
people infected with SARS-CoV-2 from those with cross-reactive immunity to other …
people infected with SARS-CoV-2 from those with cross-reactive immunity to other …
Comparison of next-generation sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes
Affordable next-generation sequencing (NGS) technologies for hepatitis C virus (HCV) may
potentially identify both viral genotype and resistance genetic motifs in the era of directly …
potentially identify both viral genotype and resistance genetic motifs in the era of directly …
[HTML][HTML] Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus
Outcomes of hepatitis C virus (HCV) infection and treatment depend on viral and host
genetic factors. Here we use human genome-wide genotyping arrays and new whole-genome …
genetic factors. Here we use human genome-wide genotyping arrays and new whole-genome …